

Special Issue

Hospital-Associated Infectious Diseases and Antibiotic Therapy

Message from the Guest Editors

Hospital-associated infectious diseases represent a significant public health issue, leading to prolonged hospital stays with considerable costs for the healthcare system. Their spread is responsible for an increased use of antimicrobial therapy, an important driver in the development of multidrug-resistant (MDR) microorganisms. Appropriate interventions in terms of infection prevention and control measures are required to mitigate the burden of these infections. This Special Issue seeks to publish research articles and reviews investigating the epidemiology, preventive measures and diagnostic tools associated with hospital-associated infectious diseases, as well as the appropriate use of antimicrobial therapy for their management, with a particular focus on the treatment of MDR pathogens and the activity of new drugs against these pathogens.

Guest Editors

Dr. Carola Mauri

Clinical Microbiology and Virology Unit, "A. Manzoni" Hospital, 23900 Lecco, Italy

Dr. Alessandra Consonni

Clinical Microbiology and Virology Unit, "A. Manzoni" Hospital, 23900 Lecco, Italy

Deadline for manuscript submissions

31 December 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/233408

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)